Amarin Corp. (AMRN) option implied volatility elevated into sharp rally on release of patient study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street rallies as AI optimism reignites and Treasury yields retreat
Amgen (AMGN) Rumored as Potential Amarin (AMRN) Suitor
September 24, 2018 12:51 PM EDTChatter Amgen (NASDAQ: AMGN) could be looking to acquire Amarin Corp. (NASDAQ: AMRN), according to STAT's Adam Feuerstein (LINK)
Amarin Corporation (AMRN) PT Raised to $15 at Cantor Fitzgerald
September 24, 2018 10:05 AM EDTCantor Fitzgerald analyst Louise Chen raised the price target on Amarin Corporation (NASDAQ: AMRN) to $15.00 (from $10.00) while maintaining a Overweight rating.
The raised PT is the result of Chen increasing her estimates for peak sales for Vascepa to $1.1 billion from $648.2 million.... More
Amarin (AMRN) Isn't Focused on Selling Company, Management Says of Conf. Call - Bloomberg
September 24, 2018 8:39 AM EDTAmarin Corp. (NASDAQ: AMRN) Isn't Focused on Selling Company, Management Says of Conf. Call - Bloomberg
... MoreAmarin Corp. (AMRN) Surges 278% on Positive Study Results
September 24, 2018 6:31 AM EDTAmarin Corp. (NASDAQ: AMRN) is surging 278% in pre-open trade after the company announced topline results from the Vascepa® cardiovascular (CV) outcomes trial, REDUCE-IT, a global... More
